HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer (HOLEP-RTPC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03802851 |
Recruitment Status :
Recruiting
First Posted : January 14, 2019
Last Update Posted : August 3, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prostate Cancer Lower Urinary Tract Symptoms | Procedure: Holmium Laser Enucleation of Prostate (HoLEP) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | This is a small scale study with initial enrollment of 20 patients in the treatment arm of the study and an additional 10 patients enrolled in the control arm of the study. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer |
Actual Study Start Date : | September 19, 2019 |
Estimated Primary Completion Date : | January 2030 |
Estimated Study Completion Date : | January 2035 |

Arm | Intervention/treatment |
---|---|
Experimental: Holmium Laser Enucleation of Prostate (HoLEP)
Patients in this arm will undergo holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS). Patients will undergo HoLEP one time and will return for standard of care follow up.
|
Procedure: Holmium Laser Enucleation of Prostate (HoLEP)
Holmium laser enucleation of the prostate (HoLEP) is a surgical treatment use for men with bothersome lower urinary tract symptoms (LUTS) to improve their LUTS. During the procedure a thin telescope-like instrument is inserted into the urethra. The high-powered laser is then inserted through this instrument and used to carefully remove the excess prostate tissue that is causing obstruction of the urethra and contributing to the patient's lower urinary tract symptoms. |
No Intervention: Control Arm
Patients in this arm will undergo no additional interventions and will not undergo holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms and instead follow standard of care treatment and follow up.
|
- Improvement in Quality of Life - One Year Post Operatively [ Time Frame: Quality of life will be assessed one year post-operatively ]The primary object is to determine if holmium laser enucleation of the prostate (HoLEP) improves the quality of life in patients with concurrent prostate cancer who may undergo radiation therapy as well. Quality of life will be assessed using the Expanded Prostate Cancer Index Composite (EPIC) 26. This instrument evaluates patient function and bother after prostate cancer treatment using 26 items and scored on a 0-100 scale, with higher scores indicating a better health related quality of life.
- Improvement in Quality of Life - Five Years Post Operatively [ Time Frame: Quality of life will be assessed five years post-operatively ]The primary object is to determine if holmium laser enucleation of the prostate (HoLEP) improves the quality of life in patients with concurrent prostate cancer who may undergo radiation therapy as well. Quality of life will be assessed using the Expanded Prostate Cancer Index Composite (EPIC) 26. This instrument evaluates patient function and bother after prostate cancer treatment using 26 items and scored on a 0-100 scale, with higher scores indicating a better health related quality of life.
- Prostate Cancer Treatment Course - One Year Post Operatively [ Time Frame: Prostate Cancer Treatment Course will assessed one year post-operatively ]The secondary objective is to determine if holmium laser enucleation of the prostate (HoLEP) alters the prostate cancer treatment course in patients. This will assessed by comparing the time from enrollment to the time of initiation of radiation therapy in patients in both arms.
- Prostate Cancer Treatment Course - Five Years Post Operatively [ Time Frame: Prostate Cancer Treatment Course will assessed five years post-operatively ]The secondary objective is to determine if holmium laser enucleation of the prostate (HoLEP) alters the prostate cancer treatment course in patients. This will assessed by comparing the time from enrollment to the time of initiation of radiation therapy in patients in both arms.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients must be 18 years of age or older
- Patients must have bothersome lower urinary tract symptoms (LUTS), defined by American Urological Association Symptom Score (AUA SS) of greater than or equal to 15 and/or as defined by a post-void residual of greater than or equal to 350mL and/or as defined by catheter dependence
- Patients must be diagnosed with prostate cancer by pathological tissue analysis
- Patients must have elected for radiation with androgen deprivation therapy as the primary treatment modality for their prostate cancer
Exclusion Criteria:
- Patients who are under 18 years of age are not eligible
- Patients who have a diagnosis of bladder cancer are not eligible.
- Patients with prior treatment for prostate cancer are not eligible.
- Patients with any type of prior prostate surgery (minimally invasive, endoscopic, or otherwise) including prior transurethral resection of the prostate (but excluding prior prostate biopsy) are ineligible.
- Patients with known metastatic prostate cancer are ineligible
- Patients who are enrolled in other surgical or international trials at the time of this study are not eligible

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03802851
Contact: Alexandra Dahlgren | 913-574-0847 | adahlgren@kumc.edu |
United States, Kansas | |
University of Kansas Health System | Recruiting |
Kansas City, Kansas, United States, 66160 |
Responsible Party: | University of Kansas Medical Center |
ClinicalTrials.gov Identifier: | NCT03802851 |
Other Study ID Numbers: |
143226 |
First Posted: | January 14, 2019 Key Record Dates |
Last Update Posted: | August 3, 2021 |
Last Verified: | July 2021 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Prostatic Neoplasms Lower Urinary Tract Symptoms Genital Neoplasms, Male Urogenital Neoplasms |
Neoplasms by Site Neoplasms Prostatic Diseases Urological Manifestations |